At the Asian Oncology Society 2023 (AOS 2023), an interim report on the Phase I/II trial of GAIA-102 for patients with microsatellite stable (MSS) advanced gastric/pancreatic cancer with malignant ascites was presented.

Dr. Mitsuhiko OTA (Department of Surgery and Science, Graduate School of Medical Sciences, Kyushu University) presented a portion of the results from ‘GAIA-102 Intraperitoneal Administration in Patients With Advanced Gastrointestinal Cancer of Microsatellite Stable With Malignant Ascites’ conducting at Kyushu University Hospital, as an interim report at the Asian Oncology Society 2023 (AOS 2023).
The principal investigator of the trial is Dr. Eiji OKI (Department of Surgery and Science, Graduate School of Medical Sciences, Kyushu University).

The summary of the presentation is as follows:

Title: Phase I/II clinical trial of repeated intraperitoneal administration of GAIA-102 in patients with microsatellite stable (MSS) advanced gastric/pancreatic cancer with malignant ascites
Author: Mitsuhiko OTA
Session: AOS Oral Session 12
Presentation No.: AOSO-12-5
Scheduled for: Thursday, October 19 16:00～17:20 Room20（Pearl, 1F, InterContinental Yokohama Grand）

https://clinicaltrials.gov/study/NCT05438459
https://congress.jsco.or.jp/aos2023/

Share on